Drug Trial Radar · NCT03604198
Extension Study to Evaluate the Safety of Long-Term Use of Relacorilant in Patients With Cushing Syndrome
Last checked: Nov 19, 2026Latest source record: Nov 3, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
125
Actual
Start
May 7, 2018
Primary completion
Dec 2026
Study completion Dec 2026
Sponsor
- Lead sponsor
- Corcept TherapeuticsIndustry
- Sponsor type
- Industry
- First posted
- Jul 27, 2018
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is an open-label extension study to evaluate the long-term safety of relacorilant in patients with endogenous Cushing syndrome who successfully completed participation in a Corcept-sponsored study of relacorilant and may benefit from continuing treatment.
Conditions
- Cushing Syndrome
Interventions
relacorilantDrug
CORT125134 is supplied as capsules for oral dosing.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Long-term safety of relacorilantTime frame: 36 months
Locations
48 sites in 10 countries. Site status is shown where the registry gives one.
Site 49
Phoenix, Arizona
Site 35
Stanford, California
Site 39
Torrance, California
Site 50
Miami, Florida
Site 10
Atlanta, Georgia
Site 9
Chicago, Illinois
Site 1
Indianapolis, Indiana
Site 5
Metairie, Louisiana
Site 27
Baltimore, Maryland
Site 13
Fall River, Massachusetts
Site 8
Ann Arbor, Michigan
Site 36
Rochester, Minnesota
Site 34
Jackson, Mississippi
Site 3
St Louis, Missouri
Site 55
Reno, Nevada
Site 6
Albany, New York
Site 24
New York, New York
Site 4
Wilmington, North Carolina
Site 43
Cleveland, Ohio
Site 2
Pittsburgh, Pennsylvania
Site 46
Pittsburgh, Pennsylvania
Site 11
Dallas, Texas
Site 7
El Paso, Texas
Site 32
Fort Worth, Texas
Site 12
Houston, Texas
Site 14
Vienna, Austria
Site 51
Nova Scotia, Canada
Site 16
Munich, Germany
Site 42
Würzburg, Germany
Site 20
Ramat Gan, Israel
Site 29
Tel Aviv, Israel
Site 40
Ancona, Italy
Site 44
Messina, Italy
Site 25
Milan, Italy
Site 21
Naples, Italy
Site 48
Padova, Italy
Site 52
Torino, Italy
Site 33
Rotterdam, Netherlands
Site 47
Krakow, Poland
Site 45
Lublin, Poland
Showing 40 of 48 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.